ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Effects of testosterone and nandrolone on cardiac function
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 188145" data-attributes="member: 3"><p><strong><span style="font-size: 18px">Effects of testosterone and nandrolone on cardiac function: a randomized, placebo-controlled study</span></strong></p><p>Chung, T ; Kelleher, S ; Liu, P. Y ; Conway, A. J ; Kritharides, L ; Handelsman, D. J</p><p>Clinical Endocrinology, 2007-02, Vol.66 (2), p.235-245</p><p></p><p></p><p>Summary Background Androgens have striking effects on skeletal muscle, but the effects on human cardiac muscle function are not well defined, neither has the role of metabolic activation (aromatization, 5α reduction) of testosterone on cardiac muscle been directly studied. Objective To assess the effects of testosterone and nandrolone, a non-amplifiable and non-aromatizable pure androgen, on cardiac muscle function in healthy young men. Design Double-blind, randomized, placebo-controlled, three-arm parallel group clinical trial. Setting Ambulatory care research centre. Participants Healthy young men randomized into three groups of 10 men. Intervention Weekly intramuscular injections of testosterone (200 mg mixed esters), nandrolone (200 mg nandrolone decanoate) or matching (2 ml arachis oil vehicle) placebo for 4 weeks. Main outcome measures Comprehensive measures of cardiac muscle function involving transthoracic cardiac echocardiography measuring myocardial tissue velocity, peak systolic strain and strain rates, and bioimpedance measurement of cardiac output and systematic vascular resistance. Results Left ventricular (LV) function (LV ejection fraction, LV modified TEI index), right ventricular (RV) function (ejection area, tricuspid annular systolic planar motion, RV modified TEI index) as well as cardiac afterload (mean arterial pressure, systemic vascular resistance) and overall cardiac contractility (stroke volume, cardiac output) were within age- and gender-specific reference ranges and were not significantly (P < 0·05) altered by either androgen or placebo over 4 weeks of treatment. <strong>Minor changes remaining within normal range were observed solely within the testosterone group for: increased LV end-systolic diameter (30 ± 7 vs. 33 ± 5 mm, P = 0·04) and RV end-systolic area (12·8 ± 1·3 vs. 14·6 ± 3·3 cm2, P = 0·04), reduced LV diastolic septal velocity (Em, 9·5 ± 2·6 vs. 8·7 ± 2·0 cm/s, P = 0·006), increased LV filling pressure (E/Em ratio, 7·1 ± 1·6 vs. 8·3 ± 1·8, P = 0·02) and shortened PR interval on the electrocardiogram (167 ± 13 vs. 154 ± 12, P = 0·03). Conclusion</strong> <strong>Four weeks of treatment with testosterone or nandrolone had no benefitial or adverse effects compared with placebo on cardiac function in healthy young men.</strong></p><p></p><p>The study was approved by the Human Ethics Committee of the</p><p>Central Sydney Area Health Service (Concord Zone). Healthy young</p><p>men aged 18–45 years were eligible for the study. Exclusion criteria</p><p>included (i) contraindications to testosterone administration (breast</p><p>or prostate cancer); (ii) previous or current use of androgens; (iii) use</p><p>of disallowed (including illicitly obtained) drugs that may interfere</p><p>with androgen absorption, distribution, metabolism, excretion or</p><p>action (e.g. androgens, anti-androgens, finasteride); (iv) any chronic</p><p>medical condition requiring regular medication or likely to interfere</p><p>with safe participation; (v) and significant cardiac disease or abnormal</p><p>baseline echocardiogram. All participants were warned about risks</p><p>of disqualification from elite sports and temporary lowering of male</p><p>fertility arising from participation in the study and were required to</p><p>provide written informed consent prior to entry.</p><p>Immediately prior to first treatment, volunteers (n= 30) were allocated to three equal groups according to a computer-generated randomization list with a block size of 6. The randomization list was</p><p>held in the pharmacy that drew up all injections to maintain blinding</p><p>of study personnel. <strong>Each group received 4 weekly intramuscular</strong></p><p><strong>injections of either 200 mg testosterone esters (Sustanon), 200 mg</strong></p><p><strong>nandrolone decanoate (Deca Durabolin), or placebo (arachis oil</strong></p><p><strong>vehicle) from Organon </strong>(Australia) Pty Ltd. All injections were</p><p>administered by study personnel.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 188145, member: 3"] [B][SIZE=18px]Effects of testosterone and nandrolone on cardiac function: a randomized, placebo-controlled study[/SIZE][/B] Chung, T ; Kelleher, S ; Liu, P. Y ; Conway, A. J ; Kritharides, L ; Handelsman, D. J Clinical Endocrinology, 2007-02, Vol.66 (2), p.235-245 Summary Background Androgens have striking effects on skeletal muscle, but the effects on human cardiac muscle function are not well defined, neither has the role of metabolic activation (aromatization, 5α reduction) of testosterone on cardiac muscle been directly studied. Objective To assess the effects of testosterone and nandrolone, a non-amplifiable and non-aromatizable pure androgen, on cardiac muscle function in healthy young men. Design Double-blind, randomized, placebo-controlled, three-arm parallel group clinical trial. Setting Ambulatory care research centre. Participants Healthy young men randomized into three groups of 10 men. Intervention Weekly intramuscular injections of testosterone (200 mg mixed esters), nandrolone (200 mg nandrolone decanoate) or matching (2 ml arachis oil vehicle) placebo for 4 weeks. Main outcome measures Comprehensive measures of cardiac muscle function involving transthoracic cardiac echocardiography measuring myocardial tissue velocity, peak systolic strain and strain rates, and bioimpedance measurement of cardiac output and systematic vascular resistance. Results Left ventricular (LV) function (LV ejection fraction, LV modified TEI index), right ventricular (RV) function (ejection area, tricuspid annular systolic planar motion, RV modified TEI index) as well as cardiac afterload (mean arterial pressure, systemic vascular resistance) and overall cardiac contractility (stroke volume, cardiac output) were within age- and gender-specific reference ranges and were not significantly (P < 0·05) altered by either androgen or placebo over 4 weeks of treatment. [B]Minor changes remaining within normal range were observed solely within the testosterone group for: increased LV end-systolic diameter (30 ± 7 vs. 33 ± 5 mm, P = 0·04) and RV end-systolic area (12·8 ± 1·3 vs. 14·6 ± 3·3 cm2, P = 0·04), reduced LV diastolic septal velocity (Em, 9·5 ± 2·6 vs. 8·7 ± 2·0 cm/s, P = 0·006), increased LV filling pressure (E/Em ratio, 7·1 ± 1·6 vs. 8·3 ± 1·8, P = 0·02) and shortened PR interval on the electrocardiogram (167 ± 13 vs. 154 ± 12, P = 0·03). Conclusion[/B] [B]Four weeks of treatment with testosterone or nandrolone had no benefitial or adverse effects compared with placebo on cardiac function in healthy young men.[/B] The study was approved by the Human Ethics Committee of the Central Sydney Area Health Service (Concord Zone). Healthy young men aged 18–45 years were eligible for the study. Exclusion criteria included (i) contraindications to testosterone administration (breast or prostate cancer); (ii) previous or current use of androgens; (iii) use of disallowed (including illicitly obtained) drugs that may interfere with androgen absorption, distribution, metabolism, excretion or action (e.g. androgens, anti-androgens, finasteride); (iv) any chronic medical condition requiring regular medication or likely to interfere with safe participation; (v) and significant cardiac disease or abnormal baseline echocardiogram. All participants were warned about risks of disqualification from elite sports and temporary lowering of male fertility arising from participation in the study and were required to provide written informed consent prior to entry. Immediately prior to first treatment, volunteers (n= 30) were allocated to three equal groups according to a computer-generated randomization list with a block size of 6. The randomization list was held in the pharmacy that drew up all injections to maintain blinding of study personnel. [B]Each group received 4 weekly intramuscular injections of either 200 mg testosterone esters (Sustanon), 200 mg nandrolone decanoate (Deca Durabolin), or placebo (arachis oil vehicle) from Organon [/B](Australia) Pty Ltd. All injections were administered by study personnel. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Effects of testosterone and nandrolone on cardiac function
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top